Inotuzumab Ozogamicin Market Size, Competitive Landscape, Revenue Analysis, 2022–2027
Inotuzumab Ozogamicin Market is a combination of a monoclonal antibody and a chemotherapy drug used to treat B-cell acute lymphoblastic leukemia (ALL) that has relapsed or is unresponsive to treatment.
The FDA has approved inotuzumab ozogamicin for treating adults with relapsed or refractory B-cell precursor ALL. The antibody component of inotuzumab ozogamicin binds to CD22 receptors, which...
0 Comments
0 Shares
2050 Views
Chinese
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek